Clinical Trial Update: Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety, pharmacokinetics and pharmacodynamics of OPT-302 with or without Lucentis in patients with wet age-related macular degene…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• OPT-302

Snippet

Sponsor: Opthea Limited | Conditions: Eye Diseases, Macular Degeneration | Phase 1 | Status: COMPLETED